scholarly journals HARAPAN PADA PENYAKIT GINJAL KRONIS TAHAP AKHIR (PGKTA) : SYSTEMATIC REVIEW

2019 ◽  
Vol 2 (2) ◽  
pp. 41
Author(s):  
Nining Puji Astuti
Keyword(s):  
Systematic Review ◽  
Renal Failure ◽  
Renal Disease ◽  
Full Text ◽  
End Stage Renal Disease ◽  
End Stage Renal Failure ◽  
Herth Hope Index ◽  
Trait Hope ◽  
Stage Renal Disease ◽  
End Stage

Latar belakang:. Harapan merupakan faktor prediktor independen yang berhubungan langsung dengan kualitas hidup PGKTA. Harapan memiliki peran penting untuk meningkatkan motivasi, koping, kemauan menjalani pengobatan dan outcome positif PGKTA.Tujuan: Tujuan dari sistematic review ini adalah untuk mengidentifikasi konsep harapan berdasarkan definisi dan instrumen yang dapat digunakan untuk mengukur harapan PGKTA, mengidentifikasi faktor yang mempengaruhi harapan PGKTA.Metode: Metode pencarian melalui PUBMED dan Google Schoolar dengan kata kunci “hope, End Stage Renal Disease, End Stage Renal Failure, Hemodialysis”. Hanya jurnal dalam Bahasa Inggris, full text, dipublikasikan tahun 2000-2019 dan menggunakan harapan sebagai tema utama dalam pembahasan yang digunakan dalam pembuatan sistematik review ini.Hasil : Harapan di definisikan sebagai kekuatan dalam diri individu yang membantu pasien keluar dari zona sakitnya dan meningkatkan derajat kesehatannya. Alat ukur yang dapat dipakai antara lain Herth Hope Index, The Trait Hope Scale, Adult Hope Scale, Miller Hope Scale, Basic Hope Inventory.Kesimpulan: Perlu kajian lebih dalam mengenai faktor dominan yang mempengaruhi harapan untuk membantu penentuan asuhan keperawatan yang tepat terkait harapan.

The Effect of Somatostatin on the Hormonal Abnormalities of End Stage Renal Disease

1981 ◽  
Vol 9 (1) ◽  
pp. 1-5
Author(s):  
Thomas G Murray ◽  
Carol Eisen ◽  
Morris Grabie ◽  
Ellen Buerklin ◽  
Barry R Walker ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Renal Failure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Control Period ◽  
Thyroid Stimulating Hormone ◽  
Dialysis Patients ◽  
End Stage Renal Failure ◽  
Stage Renal Disease ◽  
End Stage

Patients with end stage renal disease who are maintained on haemodialysis have elevated levels of many hormones, some of which may play a role in the pathogenesis of the complications of uraemia. The infusion of synthetic somatostatin reduces the circulating level of many of these same hormones in patients with normal renal function. If the elevated hormone levels in dialysis patients could be similarly lowered, study of the pathogenitic significance of the various hormonal abnormalities would be facilitated. With this in mind, the effect of synthetic somatostatin on the circulating level of growth hormone, glucagon, insulin, gastrin, parathyroid hormone, and thyroid stimulating hormone in dialysis patients was investigated. In pilot protocol, a dose of 2 mg of somatostatin infused over 24, 18, or 12 hours (two patients each) was found to have no effect on any hormonal level. Infusion of 2 mg of somatostatin over 4 hours, however, was associated with consistent fall in the level of growth hormone (13.6 ± 6.2 to 6.53 ± 2.9, p = 0.15) and glucagon (595.0 ± 73 to 441 ± 28, p < 0.05) in each of four patients. The percentage change in the level of growth hormone and glucagon during the 4-hour somatostatin infusion was significantly different from the change occurring during a 4-hour timed control period (growth hormone —45 ± 18% vs +9 ± 7%, [p < 0.05]), (glucagon −27% ± 2% vs + 8 ± 2%, [p < 0.01]). There was no change in the level of any other hormone during the 4-hour infusion. No significant adverse effects were seen. This study suggests that the intravenous infusion of somatostatin can, at least on an acute basis, lower the level of growth hormone and glucagon in patients with end stage renal failure; and, therefore, it may be useful in further study and possibly the treatment of the hormonal abnormalities of end stage renal disease.

scholarly journals Prevalence and Associated Factors of Frailty and Mortality in Patients with End-Stage Renal Disease Undergoing Hemodialysis: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 18 (7) ◽  
pp. 3471
Author(s):  
Hyeon-Ju Lee ◽  
Youn-Jung Son
Keyword(s):  
Systematic Review ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Associated Factors ◽  
Meta Analysis ◽  
Screening Tools ◽  
Cochrane Library ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Hemodialysis is the most common type of treatment for end-stage renal disease (ESRD). Frailty is associated with poor outcomes such as higher mortality. ESRD patients have a higher prevalence of frailty. This systematic review and meta-analysis aimed to identify the prevalence and associated factors of frailty and examine whether it is a predictor of mortality among ESRD patients undergoing hemodialysis. Five electronic databases including PubMed, Embase, CINAHL, Web of Science, and Cochrane Library were searched for relevant studies up to 30 November 2020. A total of 752 articles were found, and seven studies with 2604 participants in total were included in the final analysis. The pooled prevalence of frailty in patients with ESRD undergoing hemodialysis was 46% (95% Confidence interval (CI) 34.2−58.3%). Advanced age, female sex, and the presence of diabetes mellitus increased the risk of frailty in ESRD patients undergoing hemodialysis. Our main finding showed that patients with frailty had a greater risk of all-cause mortality compared with those without (hazard ratio (HR): 2.02, 95% CI: 1.65−2.48). To improve ESRD patient outcomes, healthcare professionals need to assess the frailty of older ESRD patients, particularly by considering gender and comorbidities. Comprehensive frailty screening tools for ESRD patients on hemodialysis need to be developed.

Progressive Resistance Training in End-Stage Renal Disease: Systematic Review

2016 ◽  
Vol 44 (1) ◽  
pp. 32-45 ◽  
Author(s):  
Danwin Chan ◽  
Birinder S. Cheema
Keyword(s):  
Systematic Review ◽  
Resistance Training ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Protein Energy Malnutrition ◽  
Control Period ◽  
Progressive Resistance Training ◽  
Stage Renal Disease ◽  
End Stage ◽  
Progressive Resistance

Background: This systematic review provides an overview of the extant literature on progressive resistance training (PRT) in patients with end-stage renal disease (ESRD) and outlines recommendations for future trials. Methods: A systematic review of all published literature evaluating the chronic (>6 weeks) application of PRT in patients with ESRD using electronic databases. Results: The search yielded 16 clinical trials, including 11 randomized controlled trials (RCT), 4 uncontrolled trials and one trial involving a within-subjects control period plus RCT. RCT quality, assessed via the CONSORT statement, ranged from low (4/10) to high (10/10) with a mean score of 7.3/10; 7/11 RCT had a quality score ≥7.5. All trials evaluated chronic adaptation to PRT across a range of important outcomes. PRT can induce muscle hypertrophy and improve aspects of physical functioning and health-related quality of life in ESRD. There is preliminary evidence that PRT may reduce protein-energy malnutrition and cardiovascular disease risk factors, including C-reactive protein, total cholesterol, triglyceride, and measures of insulin resistance in patients with or at-risk of comorbid type 2 diabetes. The evidence base for PRT adapting some of the endpoints investigated to date remains inconsistent (e.g. physical performance tests, obesity outcomes), and many other pertinent clinical outcomes remain to be investigated. Conclusion: RCT are required to investigate a range of novel research questions related to the benefits and application of PRT in this cohort and its patient subgroups (e.g. diabetes, depression, dyslipidemia, etc.). Future studies must be of high methodological quality to inform clinical practice guidelines.

P97 An uncommon reason of end stage renal disease: 3 cases with joubert syndrome and renal failure

2017 ◽  
Author(s):  
Aysun Karabay Bayazit ◽  
Bahriye Atmi&scedil; ◽  
Engin Melek ◽  
Abdulsamet Ala ◽  
Merve Sapmaz ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Joubert Syndrome ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Acute Intradialytic Complications in End Stage Renal Disease on Maintenance Hemodialysis

2012 ◽  
Vol 52 (187) ◽  
Author(s):  
R K Agrawal ◽  
S Khakurel ◽  
R Hada ◽  
D Shrestha ◽  
A Baral
Keyword(s):  
Renal Failure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Tertiary Care ◽  
Cross Sectional Study ◽  
Maintenance Hemodialysis ◽  
Care Hospital ◽  
Cross Sectional ◽  
Stage Renal Disease ◽  
End Stage

Introduction: Hemodialysis is the preferred method of treatment for Nepalese patients with End Stage Renal Disease. Despite the technological advances and better understanding of physiology associated with hemodialysis, a number of complications are known to be associated with hemodialysis. This study was undertaken to study the frequency of acute intradialytic complications in patients undergoing hemodialysis. Methods: A cross-sectional study was conducted at Nephrology unit of a tertiary care hospital from 15 June, 2007 to 15 December, 2007. A total of 28 patients were included in the study. Patients with acute renal failure and acute on chronic renal failure were excluded from the study. Results: Total sessions of hemodialysis during the period were 1455. Hypotensive episode were 66 (4.5%) and was the commonest complication and followed by hypertensive episodes were 58 (3.8%). Other problems encountered were transfusion reactions were 23 episodes (1.5%), rigors not related to transfusions were 13 episodes (0.8%), nausea/vomiting were 20 episodes (1.4%), muscle cramps were 12 episodes (0.8%), hypoglycemia were 6 episodes 5(0.4%). Conclusions: The frequency of intradialytic complications is low and many of them are not life threatening. Keywords: complications; end stage renal disease; hemodialysis; hypertension; hypotension.

Sign in / Sign up

Export Citation Format

Share Document